Setting research priorities to reduce almost one million deaths from birth asphyxia by 2015 by Lawn, Joy E. et al.
eCommons@AKU
Woman and Child Health Division of Woman and Child Health
January 2011
Setting research priorities to reduce almost one
million deaths from birth asphyxia by 2015
Joy E. Lawn
Rajiv Bahl
Staffan Bergstrom
Zulfiqar Ahmed Bhutta
Aga Khan University, zulfiqar.bhutta@aku.edu
Gary L. Darmstadt
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_wc
Part of the Health Services Research Commons, and the Maternal and Child Health Commons
Recommended Citation
Lawn, J., Bahl, R., Bergstrom, S., Bhutta, Z. A., Darmstadt, G., Ellis, M., English, M., Kurinczuk, J., Lee, A., Merialdi, M., Mohamed, M.,
Osrin, D., Pattinson, R., Paul, V., Ramji, S., Saugstad, O., Sibley, L., Singhal, N., Wall, S., Woods, D., Wyatt, J., Chan, K., Rudan, I.
(2011). Setting research priorities to reduce almost one million deaths from birth asphyxia by 2015. PLOS Medicine, 8(1), 389.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/69
Authors
Joy E. Lawn, Rajiv Bahl, Staffan Bergstrom, Zulfiqar Ahmed Bhutta, Gary L. Darmstadt, Matthew Ellis, Mike
English, Jennifer J. Kurinczuk, Anne C. C. Lee, Mario Merialdi, Mohamed Mohamed, David Osrin, Robert
Pattinson, Vinod Paul, Siddarth Ramji, Ola D. Saugstad, Lyn Sibley, Nalini Singhal, Steven N. Wall, Dave
Woods, John Wyatt, Kit Yee Chan, and Igor Rudan
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/69
1
Guidelines and Guidance
Setting Research Priorities to Reduce Almost One Million
Deaths from Birth Asphyxia by 2015
Joy E. Lawn1*, Rajiv Bahl2, Staffan Bergstrom3, Zulfiqar A. Bhutta4, Gary L. Darmstadt5, Matthew Ellis6,
Mike English7, Jennifer J. Kurinczuk8, Anne C. C. Lee9, Mario Merialdi10, Mohamed Mohamed11, David
Osrin12, Robert Pattinson13, Vinod Paul14, Siddarth Ramji15, Ola D. Saugstad16, Lyn Sibley17, Nalini
Singhal18, Steven N. Wall19, Dave Woods20, John Wyatt21, Kit Yee Chan22", Igor Rudan23"
1 Saving Newborn Lives/Save the Children, Cape Town, South Africa, 2Department for Child and Adolescent Health and Development, World Health Organization,
Geneva, Switzerland, 3Division of Global Health, Karolinska Institutet, Stockholm, Sweden, and Averting Maternal Death and Disability Program, Columbia University, New
York, New York, United States of America, 4Division of Women & Child Health, the Aga Khan University, Karachi, Pakistan, 5 Family Health Division, Global Health Program,
Bill & Melinda Gates Foundation, Seattle, Washington, United States of America, 6Community Child Health Partnership, Southmead Hospital, Bristol, United Kingdom,
7 KEMRI–Wellcome Trust Programme, Centre for Geographic Medicine Research–Coast, Nairobi, Kenya, and Department of Paediatrics, University of Oxford, Oxford,
United Kingdom, 8 The National Perinatal Epidemiology Unit, University of Oxford, Oxford, United Kingdom, 9Department of International Health, Johns Hopkins
Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 10Department of Reproductive Health and Research, World Health Organization,
Geneva, Switzerland, 11George Washington University, Washington, D.C., United States of America, 12Centre for International Health and Development, UCL Institute of
Child Health, London, United Kingdom, 13MRC Maternal and Infant Heath Care Strategies Research Unit at the University of Pretoria, Pretoria, South Africa,
14Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India, 15Department of Pediatrics, Maulana Azad Medical College, New Delhi, India,
16Department of Pediatric Research, Oslo University Hospital Rikshospitalet, University of Oslo, Norway, 17Nell Hodgson Woodruff School of Nursing, Atlanta, Georgia,
United States of America, 18Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada, 19 Saving Newborn Lives/Save the Children, Washington, D.C.,
United States of America, 20University of Cape Town and the Perinatal Education Programme, Observatory, South Africa, 21Centre for Philosophy, Justice and Health,
University College of London, London, United Kingdom, and Center for Women’s Health, University College of London, London, United Kingdom, 22Nossal Institute of
Global Health, University of Melbourne, Melbourne, Australia, 23Croatian Centre for Global Health, University of Split Medical School, Split, Croatia, and the Centre for
Population Health Sciences, The University of Edinburgh Medical School, Edinburgh, United Kingdom
Introduction
The Millennium Development Goals (MDGs), ratified by
almost every country in the world, have catalyzed policy attention
and investment for child survival (MDG 4) and maternal health
(MDG 5) [1]. MDG 4 aims for a two-thirds reduction in deaths of
children under 5 years of age between 1990 and 2015. Despite
almost no progress for MDG 4 on a global level during the 1990s,
there has been increasingly rapid progress with several recent
landmark achievements since about 2005. The number of child
deaths has been reduced to about 8 million per year, despite the
continuing increase in the global child population [2,3], and a
number of low-income countries are now on track for the goal [3].
On the African continent, which has had the slowest progress,
several countries have moved from the ‘‘no progress’’ to the ‘‘rapid
progress’’ group, and two low-income African countries (Eritrea
and Malawi) are on track to achieve their MDG 4 goal [4,5].
Global Burden of ‘‘Birth Asphyxia’’
Most of the child mortality reduction in recent decades, however,
is attributed to progress in tackling infectious causes of deaths (such
as measles, malaria, pneumonia, and diarrhea) in post-neonatal
infants and children aged 1–4 years. Reductions in deaths that occur
in the neonatal period (the first 28 days after birth) have been
relatively limited. When the MDGs were signed in the year 2000,
approximately 37% of under-five child deaths occurred in the
neonatal period [6]; this has since risen to over 41% [7], a total of
3.6 million deaths. Mortality in the first week after birth, the early
neonatal period, has shown the least progress, with no measurable
change at global level in the last decade. If progress towards MDG 4
is to be accelerated, then urgent attention is required to reduce
neonatal deaths. It also links closely with advancing MDG 5 since
women’s health and health care, especially at the time of birth, are
major determinants of early neonatal deaths, especially those due to
preterm birth and complications at birth.
The terms and definitions used to describe a baby affected by
birth complications have evolved over time, driven not only by a
greater understanding of pathophysiology and clinical manifesta-
tions but also by increasing litigation in high-income countries [8].
‘‘Birth asphyxia’’ is an imprecise term; it was broadly defined by
the World Health Organization (WHO) in 1997 as the clinical
description of a newborn who ‘‘fails to initiate or maintain regular
breathing at birth’’ [9]. This term applies to an important clinical
condition—the need for resuscitation—but is not predictive of
outcome. Nor does it imply a particular causation (e.g.,
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intrapartum hypoxia) since the baby may not be breathing for
other reasons, such as prematurity. Three consensus statements
have recommended that terms such as ‘‘birth asphyxia’’,
‘‘perinatal asphyxia’’, ‘‘fetal distress’’, ‘‘hypoxic-ischemic enceph-
alopathy’’, or ‘‘post-asphyxial encephalopathy’’ should not be used
unless evidence of acute intrapartum causation is available [10–
12]. These consensus statements suggested the term ‘‘neonatal
deaths associated with acute intrapartum events,’’ which is
cumbersome. Since the late 1990s, the Scottish and UK
Confidential Enquiries have included the term ‘‘intrapartum-
related neonatal death,’’ which has also been used in a recent
supplement on the topic [8]. The terminology used in interna-
tional health estimates and policy has been slower to change, but
in this paper we use the new term, intrapartum-related neonatal
deaths.
Each year an estimated 814,000 children die of intrapartum-
related causes [13]. Intrapartum-related neonatal deaths are the
fifth most common cause of under-five child deaths after
pneumonia, diarrhea, preterm birth complications, and neonatal
infections [13]. They rarely feature on lists of child survival
priorities, compared to other conditions such as malaria that
account for fewer child deaths [14]. The burden of intrapartum
complications is underestimated if only liveborn babies are
considered since an additional 1.02 million stillbirths occur in
the intrapartum period [15], which accounts for approximately
one-third of the world’s total 3.2 million stillbirths [16]. However,
stillbirths are not included in MDG tracking or Global Burden
estimation (Figure 1). The Global Burden of Disease 2004 report
allocated 42 million disability adjusted life years (DALYs) to ‘‘birth
asphyxia’’, which is twice the number of DALYs allocated to
diabetes and around 75% of the DALYs for HIV/AIDS [17].
Mismatch of Burden and Research Investment
In evidence-based decision making, research investment would
be matched with burden. There is, however, a well-described
mismatch between burden and research investment, particularly
for conditions common in low-income settings [18,19]. This
mismatch is referred to as the 10/90 gap, whereby 10% of
research expenditure is directed at 90% of the world’s burden of ill
health. The roots of this disparity are complex (see Figure 2, left
side). Even in high income countries, the research investment for
neonatal deaths is a small fraction of regular investments in
research on other conditions [20]. Although the United States
National Institutes of Health (NIH) invests approximately US$700
million on research relevant to perinatal conditions, this is less
than 1% of total NIH funding (http://report.nih.gov/rcdc/
categories/) and is primarily focused on preterm birth at around
US$1,200 per case compared to US$18,000 per case for breast
cancer and ovarian cancer. Yet the NIH allocates over US$1.9
billion to biodefense research. For low- and middle- income
countries, which experience 98% of total neonatal deaths and a
similar burden of stillbirths, the investment in research funding for
neonatal survival is extremely low, perhaps around US$20 million
per year, and the funds allocated to address intrapartum-related
conditions are even lower. Defining specific funding allocations for
research on intrapartum-related neonatal deaths is not possible in
current research resource reporting, for either high- or low-income
countries.
Given the large burden, the mismatch with investments and the
short time frame before the MDG targets in 2015, evidence-based
priority setting is imperative to accelerate progress in mortality
reduction [20]. While there are strategies to reduce intrapartum-
related neonatal deaths, the focus has been on having a functional
health system to provide care at birth [21], with little consensus on
how to strengthen weak systems over time [22], or how to address
the 60 million annual home births [23,24]. A recent series of
papers involved a systematic review of evidence for interventions
to reduce intrapartum-related deaths and screened almost 30,000
abstracts [8]. Several reviews summarized the evidence for
obstetric care and for neonatal resuscitation [25,26] and
summarized health system actions that are needed [22,27]. These
reviews focused on the need for effective implementation strategies
for intrapartum care in varying health system contexts and
consistent measurement of pregnancy outcomes including mater-
nal, neonatal and stillbirths. A previous survey of 173 policymakers
and program managers reported on implementation gaps in
programs to address intrapartum-related deaths [28]. The level of
evidence for many intrapartum interventions is low and, while
randomized trials for many accepted intrapartum care interven-
tions may not be considered ethical, all recent reviews have
highlighted the need for more investment in research [22–28]. As
yet, no publication has set out a systematic research agenda on this
topic.
Priority Setting for Research Investments
The Child Health and Nutrition Research Initiative (CHNRI),
linked with the Global Forum for Health Research, has
summarized methodologies [29] developed over the last 20 years
to set priorities for global health research investments (http://
Summary Points
N Intrapartum-related neonatal deaths (previously called
‘‘birth asphyxia’’) are the fifth most common cause of
deaths among children under 5 years of age, accounting
for an estimated 814,000 deaths each year, and also
associated with significant morbidity, resulting in a
burden of 42 million disability adjusted life years (DALYs).
N This paper uses a systematic process developed by the
Child Health Nutrition Research Initiative (CHNRI) to
define and rank research options to reduce mortality
from intrapartum-related neonatal deaths by the year
2015, in order to advance Millennium Development Goal
(MDG) 4 for child survival.
N A list of 61 research questions was developed and scored
by 21 technical experts. The top one-third of the ranked
research investment options was dominated by delivery
(implementation) research, whilst discovery (basic sci-
ence) questions were not ranked highly, especially for
expected reduction of mortality and inequity in the short
time to 2015.
N Among the top four research questions, two relate to
generation of demand for facility care at birth with
specific mechanisms (such as transport and communi-
cation schemes, or financial incentives and conditional
cash transfers). The other two top ranked priorities relate
to use of community cadres and the roles they might
effectively play—for example, screening for complica-
tions or supportive transfer to facilities and companion-
ship at birth. The highest ranked discovery question
concerned the interaction of hypoxia and infection, and
the highest ranked epidemiologic question addressed
prediction of intrapartum hypoxic injury.
N This exercise highlights the need for current research
investments to focus on studies most likely to result in
accelerated progress towards MDG 4 and in the countries
where the most deaths occur.
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www.chnri.org/publications.php). Previous methods have includ-
ed the Combined Approach Matrix [30] and the Delphi process
[31]. These were the starting points for the development of the
novel CHNRI approach to research priority setting, based on a
well-defined context, transparent criteria, and independent input
from investors, technical experts, and other stakeholders [31] (see
Figure 2, right side). The CHNRI methodology has been proposed
as a tool that could be used by those who develop research policy
or invest in health research [32,33]. The process examines (i) the
full spectrum of research investment options, (ii) the potential risks
and benefits that could result from investments in different
research options, and (iii) the likelihood of achieving reductions of
persisting burden of disease and disability through investments.
CHNRI methodology has now been applied to a wide range of
topics that include childhood pneumonia [34], diarrhea [35],
neonatal infections [36], zinc supplementation [37], mental health
[38], disability [39], primary health care [40], and also country-
level priority setting in South Africa [41].
Several analyses have shown that around two-thirds of neonatal
[42] and child deaths [43] could be prevented with existing
interventions, but that there is a gap in current coverage, especially
for the poorest families. The WHO’s Child and Adolescent Health
and Development Department (CAH) identified a need for a
systematic approach to setting priorities for health research that
could reduce this gap through health systems research while
maximizing reductions in the five main causes of child death
within the short time frame to the MDG 4 target. CAH recognized
the potential usefulness of the CHNRI methodology, and in 2008
initiated a process to identify health research priorities to reduce
mortality from the top five causes of child death, including
intrapartum-related neonatal deaths. Several hundred technical
experts from diverse backgrounds and all regions of the world took
part in the exercise. In this paper we present the results and
highest ranked research priorities to reduce mortality from
intrapartum-related neonatal deaths by 2015.
Methods
The CHNRI methodology for setting priorities in health
research investments has four stages: defining the context and
criteria for priority setting with input from investors and policy-
makers; listing and scoring research investment options by
technical experts using predetermined criteria (Box 1); weighting
the criteria according to wider societal values with input from
other stakeholders; and computation and discussion of the scores
and agreement between experts [32,33,44]. The CHNRI
Figure 1. The burden of intrapartum-related neonatal deaths, intrapartum stillbirths, maternal deaths, and the unknown
associated burden of neonatal morbidity and disability. Data sources: neonatal deaths [13], stillbirths [15,16], maternal deaths [48], place of
birth [8]. No systematic estimates are currently available.
doi:10.1371/journal.pmed.1000389.g001
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methodology, validity and potential limitations are detailed in
Table S1.
Stage 1: Define the Context and Criteria for Priority
Setting
The aim of this particular exercise was to inform key global
donors, investors in health research (especially of public funds),
and international agencies about research investment policies that
are expected to address MDG 4 in the most effective way. In
choosing to focus on mortality, we nonetheless acknowledge the
importance of non-fatal outcomes, such as the considerable
burden of morbidity and sequelae related to intrapartum insults.
In addition, while focusing on one condition (intrapartum-related
neonatal deaths), there would be expected beneficial effects of
investments from such research on related outcomes such as
maternal deaths and stillbirths, and perhaps on the function of
health systems and primary health care [9]. Furthermore, by
setting a relatively short time frame (2015), research requiring a
longer lead time was less likely to be highly ranked.
Stage 2: List and Score Research Options Using
Predetermined Criteria
Individuals with a wide range of technical expertise and regional
representation were identified by a core team and by WHO staff
and sent a formal invitation to participate. A list of research
questions was drafted by the core team expert group based on
recent systematic reviews [22–27] and a previous survey of experts
[28]. The research questions were organized using the framework
shown in Table S2. The expert group then reviewed the questions,
adding to and refining the list. The final questions were sent to
each technical group member in an Excel (Microsoft Word 2007)
format for scoring.
Based on CHNRI methodology (Figure 1), five scoring criteria
were applied: (i) answerability in an ethical way; (ii) likelihood of
Figure 2. Conceptual framework for Child Health and Nutrition Initiative (CHNRI) showing steps from health research investment
to a decrease in burden of death, disease, or disability. Investment decisions in health research are based on a range of factors and processes
(left side). The CHNRI framework identifies criteria to discriminate between competing research options (right side): (1) answerability; (2) effectiveness;
(3) deliverability; (4) maximum potential for disease burden reduction; and (5) predicted equity effect in the population. These five criteria are used to
score the list of research options in the CHNRI research priority setting process [32–34].
doi:10.1371/journal.pmed.1000389.g002
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Box 1. Questions Answered by Technical Experts to Assign Intermediate Scores to Competing
Research Options.
Possible answers: Yes = 1; No= 0; Informed but undecided
answer: 0.5; Not sufficiently informed: blank.
CRITERION 1: Likelihood that research would lead to
new knowledge (enabling a development/planning
of an intervention) in ethical way.
1. Would you say the research question is well framed and
endpoints are well defined?
2. Based on: (i) the level of existing research capacity in
proposed research; and (ii) the size of the gap from current
level of knowledge to the proposed endpoints; would you
say that a study can be designed to answer the research
question and to reach the proposed endpoints of the
research?
3. Do you think that a study needed to answer the proposed
research question would obtain ethical approval without
major concerns?
CRITERION 2: Assessment of likelihood that the inter-
vention resulting from proposed research would be
effective.
1. Based on the best existing evidence and knowledge, would
the intervention which would be developed/improved
through proposed research be efficacious?
2. Based on the best existing evidence and knowledge, would
the intervention which would be developed/improved
through proposed research be effective?
3. If the answer to either of the previous two questions is
positive, would you say that the evidence upon which
these opinions are based is of high quality?
CRITERION 3: Assessment of deliverability, afforda-
bility, and sustainability of the intervention resulting
from proposed research.
1. Taking into account the level of difficulty with intervention
delivery from the perspective of the intervention itself (e.g.,
design, standardization, safety), the infrastructure required
(e.g., human resources, health facilities, communication
and transport infrastructure) and users of the intervention
(e.g. need for change of attitudes or beliefs, supervision,
existing demand), would you say that the endpoints of the
research would be deliverable within the context of
interest?
2. Taking into account the resources available to implement
the intervention, would you say that the endpoints of the
research would be affordable within the context of
interest?
3. Taking into account government capacity and partnership
requirements (e.g., adequacy of government regulation,
monitoring and enforcement; governmental intersectoral
coordination, partnership with civil society and external
donor agencies; favorable political climate to achieve high
coverage), would you say that the endpoints of the
research would be sustainable within the context of
interest?
CRITERION 4: Assessment of maximum potential of
disease burden reduction. As this dimension is con-
sidered "independent" of the others, in order to score
competing options fairly, their maximum potential to reduce
disease burden should be assessed as potential impact
fraction under an ideal scenario, i.e., when the exposure
to targeted disease risk is decreased to 0% or coverage of
proposed intervention is increased to 100% (regardless of
how realistic that scenario is at the moment—that
aspect will be captured by other dimensions of priority
setting process, such as deliverability, affordability and
sustainability).
Non-existing interventions*
Maximum potential to reduce disease burden should be
computed as "potential impact fraction’’ for each proposed
research avenue, using the equation: PIF = [S(i = 1 to n) Pi (RRi-
1)]/[S(i = 1 to n) Pi (RRi-1)+1];
where PIF is ‘‘potential impact fraction’’ to reduce disease
burden through reducing risk exposure in the population
from the present level to 0% or increasing coverage by an
existing or new intervention from the present level to 100%;
RR is the relative risk given exposure level (less than 1.0 for
interventions, greater than 1.0 for risks), P is the population
level of distribution of exposure, and n is the maximum
exposure level.
Existing interventions**
Maximum potential to reduce disease burden should be
assessed from the results of conducted intervention trials; if
no such trials were undertaken, then it should be assessed as
for non-existing interventions.
Then, the following questions should be answered:
1. Taking into account the results of conducted intervention
trials**, or for the new interventions the proportion of
avertable burden under an ideal scenario*, would you say
that the successful reaching of research endpoints would
have a capacity to remove 5% of disease burden or more?
2. To remove 10% of disease burden or more?
3. To remove 15% of disease burden or more?
CRITERION 5: Assessment of the impact of proposed
health research on equity.
1. Does the present distribution of the disease burden affect
mainly the underprivileged in the population?
2. Would you say that either (i) mainly the underprivileged, or
(ii) all segments of the society equally, would be the most
likely to benefit from the results of the proposed research
after its implementation?
3. Would you say that the proposed research has the overall
potential to improve equity in disease burden distribution
in the long term (e.g., 10 years)?
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effectiveness; (iii) likelihood of deliverability, affordability, and
sustainability; (iv) maximum potential impact on burden reduc-
tion; and (v) predicted impact on equity. The experts made a
judgment on each proposed research question by answering the
questions presented in Box 1.
Stage 3: Solicit Input From Societal Stakeholders to
Weight the Criteria
The five criteria for scoring (answerability, efficacy and
effectiveness, deliverability, disease burden reduction, and effect
on equity) may be perceived to be of varying importance and the
value given to each criterion may vary with the perspective of
stakeholders. For example, parents who have experienced a
neonatal death may rate mortality reduction higher than a
research funder who may value answerability, or a health system
planner who may be most concerned with deliverability. Hence,
CHNRI undertook an exercise to poll a wide range of stakeholders
and to weight the criteria based on values assigned by them, as
described elsewhere [44]. The weights applied in this exercise are
explained in detail in Table S1.
Stage 4: Compute "Research Priority Scores" and Average
Expert Agreement
Completed worksheets were returned to the group coordinator.
The overall research priority score (RPS) was computed as the
mean of the scores for the five criteria, weighted according to the
input from the stakeholders (Table S1), according to the formula:
RPS ~ Criterion 1 score  0:96ð Þz Criterion 2 score  0:86ð Þð
z Criterion 3 score  0:86ð Þz Criterion 4 score  1:75ð Þ
z Criterion 5 score  0:91ð ÞÞ=5
Average expert agreement (AEA) scores were also computed for
each research question as the average proportion of scorers who
agreed on the 15 questions asked. This was computed for each
scored research investment option as:
AEA~
1
15
|
X15
q~1
N scorers who provided most frequent responseð Þ
N scorers who provided any responseð Þ
(where q is a question for which experts are being asked to
evaluate competing research investment options, ranging from 1 to
15). For further details regarding the choice of methods,
agreement statistics, and interpretation see Table S1.
Results
Of the 26 experts who were approached and agreed to
participate, 21 returned their scoring sheets within the allocated
time, resulting in a completion rate of 81%. The scorers were
evenly distributed across four regions (Africa [29%], Americas
[29%], Asia/Middle East [19%] and Europe [24%]), and the
regional distribution for non-responders was similar. Only 19% of
responders (four) and non-responders (one) were female. Expertise
covered clinical provision (midwifery, neonatology, obstetrics,
pediatrics, and disability care), perinatal epidemiology, public
health, and basic science, as well as both researchers and research
funders. The full list of technical experts who were invited to
participate, their expertise, and reasons for non-participation (for
those who declined or failed to respond in time) are presented in
Table S3.
The full list of 61 research options and the scores from each
individual scorer are presented in Table S4. Questions are
organized by delivery (health system research questions), develop-
ment, discovery science, and epidemiology research themes. More
questions were listed for delivery (28) than for development (11) or
epidemiology (17), and far fewer for discovery (5). The scores
ranged from 37 to 92 (potential 0 to 100), although almost all
scores were over 50, suggesting that few of the research options
were considered of little merit, and that the scoring system was
able to help distinguish between a long list of mostly valuable
options.
Table 1 shows the ten highest ranked questions after weighting.
Of these, seven (70%) are related to delivery research, two to
development research, one to epidemiological and none to
discovery science questions. In the top ten ranked questions, the
scores varied from 84 to 92. AEA varied from 0.42 to 0.79. Not
surprisingly, the highest ranked research options tended to have a
higher AEA. The lowest AEA, and also the lowest RPS, was for
the question regarding amnioinfusion, suggesting that the question
or the intervention may not have been well understood.
Two of the top four questions relate to how to most effectively
generate demand for facility care at birth with specific mechanisms
such as transport and communication schemes, or financial
incentives and conditional cash transfers. The other two relate
to use of community cadres and the roles that they might
effectively play; for example, in screening for complications or for
supportive transfer to facilities and companionship at birth.
Table 2 shows the ten lowest ranked questions after weighting,
with a range of RPS scores (37–58) and AEA scores (0.42–0.64).
Most of the five discovery research questions are among the lower
ranks, being placed at 59, 55, 54, 39, and 25, respectively. Only
two of the 11 development questions were in the lowest ten.
However, the lowest-ranked question related to development/
adaptation of amnioinfusion, which was ranked very low for
burden effect and also for effectiveness. Of the 17 epidemiology
questions, three fell in the lowest ten ranks and two related to early
identification of infants with developmental delay after neonatal
encephalopathy, with extremely low scoring for mortality
reduction. Only two delivery research questions were in the
lowest ten ranks, the lowest of which was about operationalizing
care for diabetes in pregnancy in weak health systems (rank 58);
this question scored low for burden reduction as well as for
deliverability.
Table 3 shows the highest ranked questions for each of the four
different research categories (description, discovery, development,
and delivery). The epidemiology questions with the highest ranks
(8, 11, and 19), were all questions with obvious clinical
implications—for example, early prediction of intrapartum
complications, risk of neonatal encephalopathy, or the need for
resuscitation. The highest ranked discovery question (25th) related
to the interaction of intrapartum infection/pyrexia and hypoxic
injury. Several development research options were ranked highly
(6, 10, and 16), and related to innovative technology for neonatal
resuscitation, for detection of fetal distress and to approaches to
maintaining provider competence for skills.
Discussion
As far as we know, this is the first systematically ranked research
priority list for addressing the burden of almost 1 million
intrapartum-related neonatal deaths, mostly occurring in the
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world’s poorest families and in settings with too few frontline
health workers. Three-quarters of the top ten priorities, and most
of the top one-third of 61 research investment options, were
dominated by delivery research (implementation). This is not
surprising given the large number of preventable deaths with
known solutions and the short time frame to give results in order to
contribute to achievement of MDG 4 in 2015. The greatest
immediate mortality gains could be achieved through better
implementation of existing interventions, and greater investment
in implementation research is an urgent need. The high-priority
research questions identified in this exercise also have high scores
for improving equity given the marked inequity in current
coverage data regarding care at birth [1,8,22].
Given 60 million home births each year, it is appropriate that
the top four priorities relate to closing the gap in skilled attendance
at the time of birth for women and their babies, mainly by trying
to bring them into facilities for birth through ‘‘pull’’ approaches
(conditional cash transfers) or better linkages such as transport and
communications, and to revisiting evidence-based, selective
approaches to identifying pregnancies at greatest risk. Other
themes in the ‘‘top ten’’ include improving facility based care with
strategies such as audit (ranked 5, 7), and innovations for low-cost,
simpler technology (ranks 6, 10), in addition to more questions
regarding roles for community cadres (ranks 8 and 9).The scores
for the top ten ranked options were close and it is possible that
with a larger group of experts the rank orders would differ.
However, whilst delivery research investment is most likely to
result in burden reduction in the shorter term, development and
discovery research remain essential to develop new interventions
to feed the delivery research pipeline [18]. The highest ranked
question from the discovery research options was only at 25 out of
61. The ten lowest ranked options included the other four of the
five initial discovery research options. This may reflect a systematic
bias introduced by the specified context of a very short time frame
(5 years). Discovery research often takes longer to be translated
into measurable benefits in terms of mortality burden reduction,
and by definition the link to reduction in mortality and inequity is
less direct. The highest ranked discovery question related to the
interaction of hypoxia and infection, which is particularly relevant
in high burden settings where the prevalence of both conditions is
Table 1. The 15 research questions that achieved the highest overall research priority score (RPS), with average expert agreement
(AEA) related to each question (total of 61 questions).
Rank Proposed Research Question
Research
Type
Answer-
able?
Effec-
tive?
Deliver-
able?
Burden
reduction? Equitable? AEA RPS
1 Can community cadres of workers identify a limited number
of high-risk conditions/danger signs (e.g., multiple pregnancy,
breech, short maternal stature, etc.) and successfully refer
women for facility birth? What is the predictive value and
cost effectiveness?
Delivery 93 88 85 77 94 0.78 91.9
2 What strategies are effective in increasing demand for, and
use of, skilled attendance (e.g., conditional cash transfers)?
Delivery 90 88 77 82 93 0.79 91.2
3 Behavioral/community participation package to improve
recognition and acting for simplified danger signs for mother
in labor, including transport and phone/radio communication
("emergency preparedness")?
Delivery 92 78 94 75 95 0.79 90.6
4 Effectiveness of community cadre roles, e.g., social support,
bringing to facility when woman is in labor, danger
recognition/referral?
Delivery 83 78 96 73 95 0.74 88.9
5 Does regular use of perinatal audit reduce the incidence of
adverse outcomes related to acute intrapartum events?
Delivery 83 97 82 68 98 0.74 88.4
6 Can simpler/cheaper/more robust technology be developed
for neonatal resuscitation (e.g., bag-and-mask, suction
devices), and for resuscitation training (resuscitation
dummies) and more feasible models of maintaining
clinical competency for resuscitation?
Development 95 93 87 59 100 0.78 88.1
7 Does regular use of perinatal audit improve adherence to
clinical standards for intrapartum care (e.g., use of
partograph, monitoring of fetal heart rate, resuscitation etc.)?
Delivery 78 92 82 72 93 0.69 86.6
8 Can specific maternal complications (e.g., obstructed
labor, hypertension, retained twin) with higher risk of
intrapartum stillbirth, early neonatal death, or other
unfavorable intrapartum-related outcomes be more
simply predicted at an earlier stage?
Epidemiology 85 81 82 72 91 0.74 86.2
9 Can simpler clinical algorithms (recognition and
management) be developed and validated for babies
who require resuscitation at birth, and does this
increase met need for resuscitation at birth?
Delivery 93 81 93 53 100 0.79 84.4
10 Can low-cost, robust, simple fetal heart monitors be
developed and tested that are more user friendly than
the Pinard—e.g., adaptations of Doppler FHM? Does use of
such a device improve fetal heart rate monitoring and
reduce intrapartum stillbirths and asphyxia-related outcomes?
Development 94 86 69 64 93 0.75 83.7
doi:10.1371/journal.pmed.1000389.t001
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high. Initial, small studies of head cooling for neonatal
encephalopathy in high burden settings raise the question of
whether infection may be a factor in the possible increased risk
observed with cooling [45].
The development and epidemiological research questions
mainly fell in the middle band. The highest ranked development
option refers to simpler, cheaper, more robust technology for
neonatal resuscitation, which is clearly critical given the major
unmet need [26]. The highest ranked epidemiology question also
echoed the need to revisit the radical move away from risk
screening, asking if specific maternal complications (e.g., obstruct-
ed labor, hypertension, retained twin) with higher risk of
intrapartum stillbirth, early neonatal death, or other unfavorable
asphyxia-related outcome could be more simply detected at an
earlier stage.
Although the CHNRI methodology represents a systematic
attempt to deal with many of the challenges inherent in the complex
process of research investment priority setting, there are still possible
biases [29]. The initial list of questions is critical—if a given research
investment option is not included, it cannot be scored and drops
from view. Another important possible source of bias arises from the
selection and response of the expert technical group. A larger
scoring group and deliberate attempts to widen regional and
professional variation appear to help reduce the risk of bias; in
addition, due to independent scoring of lists, the ranking is less likely
to be dominated by eloquent individuals, as may happen in
traditional group discussion approaches to research priority setting.
Limitations of CHNRI methodology and validation exercises are
described and discussed in greater detail in Table S1.
Conclusions
A strong political commitment has been made to MDG 4 and 5,
but this commitment requires systematic changes in health
research investment. Current investments mainly target the
diseases prevalent in high-income countries and tend to favor
basic research. This exercise highlights the research investments
most likely to result in rapid progress towards MDG 4 in the
Table 2. The 15 research questions that achieved the lowest overall research priority score (RPS), with average expert agreement
(AEA) related to each question (total of 61 questions).
Rank Proposed Research Question
Research
Type Answerable? Effective? Deliverable?
Burden
reduction? Equitable? AEA RPS
52 What is the magnitude of misclassification between
fresh stillbirths and early neonatal deaths, and
which factors affect this misclassification? What
decision rules (applicable in the community and
hospital settings) can be used to differentiate?
Epidemiology 77 72 58 18 67 0.57 55.8
53 What is the positive and negative predictive value
of a very low (,3) and a moderately low (4–6)
Apgar score for neonatal encephalopathy (NE),
death, etc.
Epidemiology 85 57 47 12 77 0.61 52.4
54 Can new, simple to use, robust technology be
developed to better detect neonatal
fetal distress or NE in low-income settings? e.g.,
amplitude-integrated EEG (cerebral function
monitor, CFM) to identify NE for postnatal
therapeutic interventions.
Development 75 62 23 26 79 0.66 52.4
55 What are the longer term outcomes of NE (6
months, 1 y, 5 y, and school function at 10 y),
and is there an increased risk of death as well
as disability and reduced school performance?
Epidemiology 79 81 32 11 74 0.64 51.8
56 Would novel micronutrient approaches reduce
cerebral damage after insult (magnesium,
nitrates, combinations etc.)?
Discovery 72 60 61 24 48 0.49 51.6
57 Does early identification of babies with
development problems following NE improve
utilization of services (feeding, physiotherapy,
speech and language, hearing) and/or outcomes
(hearing, vision, school performance)?
Delivery 83 43 47 4 78 0.60 46.9
58 Can care of diabetes in pregnancy be
operationalized in context of weak health
systems to reduce the risk of large for gest
age babies?
Delivery 71 44 35 25 59 0.53 46.9
59 Would other novel drug treatments reduce
cerebral damage after insult (allopurinol, epo,
opioids, etc.)?
Discovery 70 60 42 10 37 0.51 41.7
60 Are there genes or other biomarkers that predict
susceptibility to intrapartum hypoxic injury?
Discovery 50 62 10 18 48 0.60 37.0
61 Can the procedure of amnioinfusion be adapted
to lower resource settings and would this impact
asphyxia-related outcomes? Are there clinically
important risks from the procedure?
Development 50 50 27 10 52 0.42 36.0
doi:10.1371/journal.pmed.1000389.t002
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countries with the most deaths. These primarily address delivery
research and development research, particularly to increase the
reach of some high impact interventions for the poorest and most
heavily affected families. Competing research questions may all
contribute to MDG 4 and certainly for the longer term agenda
more investment is also required in discovery science. A more
systematic approach with strategic investment in different
instruments of health research would be expected to accelerate
progress towards mortality reduction. While newborn survival has
gained rapid attention in recent years, attention has yet to connect
to adequate action [46]. Further progress in reducing deaths will
depend on systematically addressing implementation and knowl-
edge gaps, and targeted innovation where most of the deaths
occur.
We challenge the research community, research funding
organizations, and national research organizations to systemati-
cally address at least the top ten ranked research questions before
2015. These research options have the potential to prevent almost
1 million unnecessary neonatal deaths that occur every year, and
also reduce an additional one million intrapartum stillbirths and
the closely associated 350,000 maternal deaths [47].
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